
Quarterly ResultNov 5, 2026, 07:42 AM
Akebia Therapeutics Q3 Revenue Down 39%; Posts Net Loss of $14.4M
AI Summary
Akebia Therapeutics, Inc. reported its third-quarter financial results for 2026, showing a significant decrease in revenue and a shift from net income to net loss compared to the same period in 2025. Product revenue declined to $34.8 million from $56.8 million year-over-year, contributing to a total revenue of $36.9 million, down from $58.8 million. The company posted a net loss of $14.4 million for the quarter, a reversal from a net income of $0.5 million in the prior year's third quarter. While R&D expenses saw a slight increase, SG&A expenses were reduced. The company's cash position also decreased.
Key Highlights
- Akebia Therapeutics reported Q3 2026 product revenue of $34.8M, a decrease from $56.8M in Q3 2025.
- Total revenues for Q3 2026 were $36.9M, down from $58.8M in Q3 2025.
- Net loss for Q3 2026 was $14.4M, compared to a net income of $0.5M in Q3 2025.
- Research and development expenses increased to $16.2M in Q3 2026 from $14.9M in Q3 2025.
- Selling, general and administrative expenses decreased to $23.5M in Q3 2026 from $29.1M in Q3 2025.
- Cash and cash equivalents decreased to $159.3M as of September 30, 2026, from $184.8M as of December 31, 2025.
Price Impact
More from AKBA